Related Experiment Video
Updated: Jun 17, 2026
07:28
Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation
Published on: October 11, 2024
Lung transplantation for cystic fibrosis
Frederick R Adler1, Paul Aurora, David H Barker
1Department of Mathematics, University of Utah, Salt Lake City, Utah 84112, USA.
Proceedings of the American Thoracic Society
|December 17, 2009
Summary
Lung transplantation offers life-saving therapy for cystic fibrosis (CF) patients. International experts convened to discuss optimizing outcomes, surgical techniques, and patient adherence for lung transplants in CF.
Area of Science:
- Pulmonology
- Transplantation Medicine
- Medical Ethics
Background:
- Cystic Fibrosis (CF) is a severe end-stage lung disease.
- Lung transplantation is a high-risk, life-saving therapy for CF patients.
- Controversies exist regarding the survival benefits of lung transplantation for CF, particularly concerning US allocation systems versus UK and Canadian studies.
Purpose of the Study:
- To address controversies surrounding lung transplantation for CF.
- To review the current state of lung transplantation for CF in an international context.
- To identify areas for improvement in CF lung transplantation outcomes and research.
Main Methods:
- International expert meeting discussing lung transplantation for CF.
- Focus on surgical techniques, outcome measurement, prognostic criteria, and listing variations.
- Consideration of patient adherence and international comparisons (US, Canada, UK, Netherlands).
Main Results:
- Discussions highlighted advances in surgical techniques and outcome measurement.
- Variations in listing and prioritization criteria across different countries were examined.
- The importance of patient adherence before and after transplantation was emphasized.
Conclusions:
- Lung transplantation remains a critical option for end-stage CF lung disease.
- International collaboration and standardized approaches are crucial for improving transplant outcomes.
- Further research is needed to optimize the study of lung transplantation in CF patients.
Related Concept Videos
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...